Sarah F Adams, Alizée J Grimm, Cheryl L-L Chiang, Ananda Mookerjee, Dallas Flies, Stephanie Jean, Georgia A McCann, Justine Michaux, HuiSong Pak, Florian Huber, Christopher Neal, Denarda Dangaj, Michal Bassani-Sternberg, Sylvie Rusakiewicz, Andrea Facciabene, George Coukos, Phyllis A Gimotty, Lana E Kandalaft
BACKGROUND: Novel therapeutic strategies in ovarian cancer (OC) are needed as the survival rate remains dismally low. Although dendritic cell-based cancer vaccines are effective in eliciting therapeutic responses, their complex and costly manufacturing process hampers their full clinical utility outside specialized clinics. Here, we describe a novel approach of generating a rapid and effective cancer vaccine using ascites-derived monocytes for treating OC. METHODS: Using the ID8 mouse ovarian tumor model and OC patient samples, we isolated ascites monocytes and evaluated them with flow cytometry, Luminex cytokine and chemokine array analysis, ex vivo cocultures with T cells, in vivo tumor challenge and T cell transfer experiments, RNA-sequencing and mass spectrometry...
August 2020: Journal for Immunotherapy of Cancer